Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index.

Yabe D, Yamada Y, Kaku K, Nishida T, Sato T, Seino Y

Journal of diabetes investigation9 Mar 2022Cited by 21 (Europe PMC)

PMID35174649PMCIDPMC9248424DOI10.1111/jdi.13773PepBankPUB-35174649

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, semaglutide 0.5 mg reduced HbA1c from baseline across age and BMI subgroups, and numerically more than comparators.
In plain wordsIn Japanese adults with type 2 diabetes, semaglutide 0.5 mg lowered HbA1c in every age and BMI subgroup, numerically more than comparators.
Peptide
Semaglutide
Outcome
DecreaseHbA1c reduction by age and BMI subgroup
Study
n: not reported in source
Comparator
Sitagliptin or oral antidiabetes drugs
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg once weeklyAs given in this study (human).
Measurements
HbA1c change
−1.7 to −2.1%
semaglutide 0.5 mg
Source sentences
Summary
Reductions from baseline in glycosylated hemoglobin ranged from -1.7 to -2.1 with semaglutide 0.5 mg
3 context sentences(design, population, supporting numbers)
Summary · context
Reductions in glycosylated hemoglobin and bodyweight were numerically greater with semaglutide versus comparators across all age and BMI subgroups.
Summary · context
Data were derived from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) Japan monotherapy and SUSTAIN Japan oral antidiabetes drug (OAD) combination trials comparing once-weekly semaglutide with sitagliptin or OADs, respectively.
Summary · context
Participants were grouped by baseline age (2 ).
Report a problemFND-3517464901
02HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, semaglutide 1.0 mg reduced HbA1c from baseline across age and BMI subgroups, and numerically more than comparators.
In plain wordsIn Japanese adults with type 2 diabetes, semaglutide 1.0 mg lowered HbA1c in every age and BMI subgroup, numerically more than comparators.
Peptide
Semaglutide
Outcome
DecreaseHbA1c reduction by age and BMI subgroup
Study
n: not reported in source
Comparator
Sitagliptin or oral antidiabetes drugs
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg once weeklyAs given in this study (human).
Measurements
HbA1c change
−1.8 to −2.4%
semaglutide 1.0 mg
Source sentences
Summary
-1.8 to -2.4 with semaglutide 1.0 mg
3 context sentences(design, population, supporting numbers)
Summary · context
Reductions in glycosylated hemoglobin and bodyweight were numerically greater with semaglutide versus comparators across all age and BMI subgroups.
Summary · context
Data were derived from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) Japan monotherapy and SUSTAIN Japan oral antidiabetes drug (OAD) combination trials comparing once-weekly semaglutide with sitagliptin or OADs, respectively.
Summary · context
Participants were grouped by baseline age (2 ).
Report a problemFND-3517464902
03HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, semaglutide 0.5 mg reduced bodyweight from baseline across age and BMI subgroups, numerically more than comparators.
In plain wordsIn Japanese adults with type 2 diabetes, semaglutide 0.5 mg lowered bodyweight in every age and BMI subgroup, numerically more than comparators.
Peptide
Semaglutide
Outcome
DecreaseBodyweight change by age and BMI subgroup
Study
n: not reported in source
Comparator
Sitagliptin or oral antidiabetes drugs
Outcome group
Body weight · Metabolic and weight
Studied dose
0.5 mg once weeklyAs given in this study (human).
Measurements
Bodyweight change
−1 to −2.5 kg
semaglutide 0.5 mg
Source sentences
Summary
Corresponding ranges for bodyweight (kg) were -1.0 to -2.5, -2.4 to -4.3 and 1.0 to -1.0 kg, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Reductions in glycosylated hemoglobin and bodyweight were numerically greater with semaglutide versus comparators across all age and BMI subgroups.
Summary · context
Data were derived from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) Japan monotherapy and SUSTAIN Japan oral antidiabetes drug (OAD) combination trials comparing once-weekly semaglutide with sitagliptin or OADs, respectively.
Summary · context
Participants were grouped by baseline age (2 ).
Report a problemFND-3517464903
04HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, semaglutide 1.0 mg reduced bodyweight from baseline across age and BMI subgroups, numerically more than comparators.
In plain wordsIn Japanese adults with type 2 diabetes, semaglutide 1.0 mg lowered bodyweight in every age and BMI subgroup, numerically more than comparators.
Peptide
Semaglutide
Outcome
DecreaseBodyweight change by age and BMI subgroup
Study
n: not reported in source
Comparator
Sitagliptin or oral antidiabetes drugs
Outcome group
Body weight · Metabolic and weight
Studied dose
1.0 mg once weeklyAs given in this study (human).
Measurements
Bodyweight change
−2.4 to −4.3 kg
semaglutide 1.0 mg
Source sentences
Summary
Corresponding ranges for bodyweight (kg) were -1.0 to -2.5, -2.4 to -4.3 and 1.0 to -1.0 kg, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Reductions in glycosylated hemoglobin and bodyweight were numerically greater with semaglutide versus comparators across all age and BMI subgroups.
Summary · context
Data were derived from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) Japan monotherapy and SUSTAIN Japan oral antidiabetes drug (OAD) combination trials comparing once-weekly semaglutide with sitagliptin or OADs, respectively.
Summary · context
Participants were grouped by baseline age (2 ).
Report a problemFND-3517464904
05HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, the safety profile of semaglutide was broadly similar across BMI and age subgroups.
In plain wordsIn Japanese adults with type 2 diabetes, semaglutide side effects were broadly similar across age and BMI groups.
Peptide
Semaglutide
Outcome
No significant changeSafety profile across age and BMI subgroups
Study
n: not reported in source
Comparator
Other age and BMI subgroups
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
The safety profile of semaglutide was broadly similar across BMI and age subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
Data were derived from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) Japan monotherapy and SUSTAIN Japan oral antidiabetes drug (OAD) combination trials comparing once-weekly semaglutide with sitagliptin or OADs, respectively.
Summary · context
Participants were grouped by baseline age (2 ).
Report a problemFND-3517464905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT07043361

Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels

Hillel Yaffe Medical Centern = 5,30018 Dec 2023 to 30 Apr 2025

Metabolic Disease

Trial page ClinicalTrials.govUpdated 9 Jul 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.